Midnight Drop: How a $16M Alzheimer's Miracle Vanished
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Midnight Drop: How a $16M Alzheimer's Miracle Vanished
-
ナレーター：
-
著者：
Hope turned to doubt overnight: a $16 million NIH grant, hundreds of patients in trials, and a drug called simufilam that rested on a disputed protein called filamin A - then every criminal charge was dropped at midnight. What happened to the biomarker data, the images that triggered retractions, and the independent verification that never arrived?
In this episode, we lay out the timeline from the 2012 Journal of Neuroscience paper that introduced PTI-125 to the 2025 courtroom where charges were dismissed, tracing the grant, the clinical trials, the failed and later conflicting biomarker results, and the unresolved scientific record. How did foundational research, public funding, and patient trials converge - and vanish - without a clear resolution?
Person: Hoau-Yan Wang
Person: Lindsay Burns
Event: Retraction of foundational opioid-related FLNA papers in 2022
Date: Phase IIb failed biomarker analysis in May 2020
Amount: $16,000,000 federal grant from NIH
- 2012: PTI-125 (later renamed simufilam) first described in the Journal of Neuroscience.
- 2017: Mouse data supporting the mechanism published in Neurobiology of Aging.
- 2018: National Institutes of Health awarded Cassava Sciences $16,000,000 to support early clinical trials.
- May 2020: Cassava's Phase IIb cerebrospinal fluid biomarker analysis initially failed to show the expected biological signal.
- 2022: Foundational FLNA opioid-related papers by Wang and Maya Frankfurt were retracted due to similarities in background pixels in western blot images.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません